Answers are grounded in this paper and cite their sources.
Low-level viremia (LLV) in chronic hepatitis B (CHB) patients receiving entecavir (ETV) therapy is associated with increased risk of hepatic fibrosis progression and hepatocellular carcinoma. Optimal management strategies for LLV remain debated. This study aimed to compare the efficacy and safety of sequential tenofovir amibufenamide (TMF) monotherapy versus ETV plus TMF combination therapy in CHB patients with LLV after prior ETV treatment. This retrospective observational cohort study enrolled 212 CHB patients with LLV (HBV DNA 20-2000 IU/mL) after ≥ 48 weeks of ETV treatment at the Third People‘s Hospital of Yunnan Province between January 2022 and December 2024. Treatment allocation was based on the regimen selected in routine clinical care. Patients were classified into either sequential TMF monotherapy (TMF group, n = 118, switching from ETV to TMF) or ETV plus TMF combination therapy (combination group, n = 94, adding TMF to ongoing ETV). Propensity score matching (1:1 ratio, logit caliper 0.02, without replacement) was performed to balance baseline covariates, yielding 60 patients per group. Virological response (HBV DNA < 20 IU/mL), HBeAg seroconversion, HBsAg decline/loss, liver function (ALT, AST), renal function (Cr, eGFR), liver stiffness measurement (LSM), lipid profiles (TC, TG, HDL-C, LDL-C), and adverse events were assessed at 48 weeks. After PSM, continuous variables were compared using paired t-tests, binary outcomes using conditional logistic regression, and continuous renal outcomes using conditional linear regression. Sensitivity analyses including double-adjusted outcome models and inverse probability of treatment weighting (IPTW) were performed. Multivariable regression was performed to identify independent predictors of virological response. After PSM, baseline characteristics were well-balanced between groups. At week 48, the combination group demonstrated significantly higher HBV DNA undetectable rate (86.67% vs. 63.33%, conditional logistic regression P = 0.003) and HBeAg seroconversion rate (58.33% vs. 36.67%, conditional logistic regression P = 0.017) compared with the TMF group. The combination group showed significantly lower ALT (24.85 ± 6.94 vs. 29.36 ± 8.17 U/L, paired t-test P = 0.001), AST (22.67 ± 5.83 vs. 27.41 ± 7.26 U/L, paired t-test P < 0.001), and LSM (6.58 ± 1.46 vs. 7.48 ± 1.72 kPa, paired t-test P = 0.003) levels post-treatment. However, the TMF group exhibited better renal preservation with higher eGFR (101.35 ± 10.84 vs. 96.28 ± 11.53 ml/min/1.73 m², paired t-test P = 0.014). Conditional linear regression in the matched cohort confirmed that combination therapy was significantly associated with greater eGFR decline (adjusted β -4.82, 95% CI -8.51 to -1.13, P = 0.011). Multivariable regression identified combination therapy (adjusted OR 3.82, 95% CI 1.58–9.24, P = 0.003), baseline HBV DNA (adjusted OR 0.71, 95% CI 0.52–0.97, P = 0.032), and baseline HBeAg positivity (adjusted OR 0.45, 95% CI 0.21–0.96, P = 0.040) as independent predictors of HBV DNA undetectable at week 48. Both groups experienced mild elevations in TC from baseline (TMF group: 5.21 ± 0.94 vs. 4.82 ± 0.89 mmol/L, P = 0.018; combination group: 5.16 ± 0.91 vs. 4.78 ± 0.86 mmol/L, P = 0.022), with no significant between-group differences. HBsAg decline at week 48 was − 0.18 ± 0.32 log₁₀ IU/mL in the TMF group vs. -0.24 ± 0.38 log₁₀ IU/mL in the combination group ( P = 0.356), with HBsAg loss occurring in 1 (1.67%) vs. 2 (3.33%) patients ( P = 1.000). Adverse event rates were comparable (TMF group: 20.00%; combination group: 18.33%; conditional logistic regression P = 0.815). Sensitivity analyses (double-adjusted models and IPTW) confirmed the robustness of these findings. In ETV-treated CHB patients with LLV, adding TMF to ongoing ETV therapy achieves superior virological response and greater improvement in noninvasive liver stiffness measures compared with switching to TMF monotherapy, whereas sequential TMF monotherapy offers better short-term renal preservation. Conditional linear regression confirmed combination therapy as an independent predictor of greater eGFR decline. Both regimens are associated with modest TC elevation, warranting regular lipid monitoring during long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: